Pharmacy and Research
From biosimilars to precision medicine to drug costs, here’s your ultimate guide to all things pharmacy and research.
-
Open File
Premier’s Roadmap for a Healthier Drug Market
Our nation's healthcare system has experienced an alarming increase in drug prices for a range of products vital to patient care.
-
Open File
Pharmaceutical Costs Remain Major Concern for Healthcare Leaders
Pharmaceutical Costs Remain Major Concern for Healthcare Leaders.
-
Open FilePremier Healthcare Database White Paper
Premier Healthcare Database has been utilized by the pharmaceutical and device industries, academia, healthcare insurers and healthcare policy makers for clinical, financial and outcomes analyses.
-
Read ArticleA Look Forward To Healthcare In 2017: Top Five Trends
Premier’s Susan DeVore discusses healthcare industry trends to expect this year, including the repeal/replacement of the Affordable Care Act, the growth and acceleration of value-based care and more.
-
Open File
Biosimilars 101: Facts, Risks & Opportunities
The emergence of biosimilars over the last few years has introduced a new competitive specialty pharmaceuticals market to combat the rising price tags on expensive biologics.
-
Read ArticleRethink: Healthcare in 2017
Here are three focus areas for the Trump Administration that will help capitalize on the healthcare gains we’ve already achieved.
-
Open FileBiosimilars: A Tipping Point
With biosimilars, the U.S. healthcare industry has a remarkable opportunity to make lifesaving and disease-altering drugs more accessible and more affordable. Read more.
-
1:11Watch VideoWhat Are Biosimilars?
Watch to learn more.
-
Open File
Economic Outlook: Fall 2016 C-Suite Survey
The fall 2016 Economic Outlook survey polled 52 health system C-suite executives from across the U.S. on some of the biggest issues facing health systems as a whole.
-
Read Article3 Action Items to Thrive in Value-Based Care
While we wait for the dust to settle from the presidential election, there is much uncertainty. However, we believe the movement away from pay-for-volume to pay-for-value will continue. Read more.
-
Read ArticleReal-World Evidence: From Volume to Value
-
Read ArticleFaster FDA Approvals of New Drugs Would Lead to Lower Prices, Says Premier CEO
Susan DeVore, CEO of healthcare company Premier, says increased competition is needed to reduce prescription drug costs.
-
Read ArticleCoalition Says Transparency, Value-based Pay Could Contain Drug Costs
Increased transparency and competition in the pharmaceutical industry and expanded value-based payment models would help address rising prescription drug prices, according to a coalition aimed at ...
-
Read ArticleUnpacking Drug Price Spikes: Generics
The generic medication market has been in turmoil—shortages, price spikes, quality issues, compounding abuse—since 2008.
-
Read ArticleThree Ways Providers Should Address Drug Shortages
Preventing drug shortages requires a “swat team” mentality by all, including FDA, manufacturers, group purchasing organizations (GPOs), and health systems.
-
Read ArticleSpecialty Pharmacy: Not for the Faint of Heart
Strategic use of specialty drugs can cure complex, chronic conditions in some cases, or dramatically reduce their medical costs in others.
-
Read ArticleHow Competition Can Bring Down Drug Prices
Premier chief executive officer, Susan DeVore, discusses today's high drug prices and shares her thoughts on how competition might be able to drive costs down.
-
Read ArticleTaking Action Against Drug Shortages
Although the severity of drug shortages has eased somewhat in recent years, providers still are frequently unable to offer patients the medications they need.
-
Read ArticleWho's Teaching Whom Biosimilars? The Rise of Patient Education
As consumers begin to adapt to the high cost of biologic medicines and their biosimilar counterparts, there may be a shift in education, with patients – not providers – leading the way.
-
Read ArticleSpecialty Pharmacy: Not for the Faint of Heart
According to the CDC, chronic diseases—such as heart disease, stroke, cancer, type 2 diabetes, obesity and arthritis—are among the most common, costly, and preventable of all health problems.
-
Loading More...
